DOSTUPNOST ORFAN LEKOVA - OSNOVNAPRAVNA PITANJA RAZVOJA I FINANSIRANJA. (Bosnian)

AVAILABILITY OF ORPHAN DRUGS - BASIC LEGAL ISSUES OF DEVELOPMENT AND FINANCING. (English)

This paper critically analyzes the basic models for the development and financing of orphan drugs, i.e. medicines for the treatment of rare diseases, starting from the principle of equality in health care proclaimed within the framework of the World Health Organization and to the protection of the rights of vulnerable categories of the population as well. A comparative and normative method has been applied. On the basis of the regulations of the European Union and the national laws of the member states, the paper emphasizes the possible solutions for the development of domestic law in the context of ensuring access to patients and exercising the right to health care. The opinion of the European Court of Human Rights in the case of Nitecki v. Poland is, specifically, analyzed from the aspect of refunding the price of an orphan medicinal product and exercising the right to access to health care services for patients. The model of public-private partnership was identified as the most adequate one in the conditions of limited public resources, taking into account the interest of the state, and the need for expressing social responsibility considering the interest of the (pharmaceutical) companies. The model is based on the (bio)ethic principle of justice, conceptualized as assistance to those people who suffer from bad health condition and who are economically worse off. [ABSTRACT FROM AUTHOR]

U radu se kritički analiziraju osnovni modeli razvoja i finansiranja orfan lekova, odnosno lekova za lečenje retkih bolesti, polazeći od principa jednakosti u zdravlju, proklamovanog u okvirima Svetske zdravstvene organizacije, i zaštite prava ranjivih kategorija stanovništva. Primenjen je uporednopravni i normativni metod, gde se na osnovama regulative Evropske unije i prava država članica ukazuje na moguće pravce razvoja domaćeg prava u kontekstu obezbeđenja dostupnosti pacijentima i ostvarivanja prava na zaštitu zdravlja. Stanovište Evropskog suda za ljudska prava u slučaju Nitecki v. Poland se, posebno, analizira sa aspekta refundacije cene orfan leka i ostvarivanja prava na dostupnost zdravstvenih usluga pacijentima. Model javno-privatnog partnerstva utvrđen je kao najadekvatniji u uslovima ograničenih javnih resursa, na strani države, i potrebe za iskazivanjem društvene odgovornosti, na strani (farmaceutskih) kompanija. [ABSTRACT FROM AUTHOR]

Copyright of Legal Records / Pravni Zapisi is the property of Union University Law School, Belgrade and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)